Actively Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2025-08-14
32
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved. Then minimally therapy like transcatheter arterial chemoembolization (TACE) could effectively stanch the ruptured tumor and bleeding vessels. Then TACE combined the Lenvatinib and PD-1 inhibitor for this subtype HCC could effectively inhibit the tumor and improve the prognosis.
CONDITIONS
Official Title
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary hepatocellular carcinoma confirmed by biopsy or clinical criteria
- Evidence of hemostasis seen on enhanced CT scan
- Tumor integrity disrupted with hematoma around the liver
- First-line systemic therapy includes Lenvatinib and PD-1 inhibitor
- Undergoing transarterial chemoembolization (TACE) as local treatment
- Child-Pugh liver function class A or B and ECOG performance status 0 to 2
- No history of other cancers
- Life expectancy longer than 3 months
- Agreement to participate in the clinical trial
- Blood counts and liver/kidney function within specified safe ranges
You will not qualify if you...
- Recurrent hepatocellular carcinoma
- Hepatocellular carcinoma without tumor rupture
- Lenvatinib and PD-1 inhibitor used as second-line or later therapy
- Age younger than 18 years or older than 75 years
- More than five metastases from hepatocellular carcinoma
- History of hepatic encephalopathy or gastrointestinal bleeding
- Life expectancy less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qunfang Zhou
Beijing, None Selected, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
M
Mingyu Liu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here